Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | KDR | P35968 | 5/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206072 | 0.87 | KDR (0.47) | EGFRKDRHPGDALDH1A1KDM4E | |
| SCHEMBL26206067 | 0.86 | EGFR (0.46) | EGFRKDREGLN2CHRNA7HTR3A | |
| SCHEMBL26206080 | 0.86 | EGFR (0.46) | EGFRKDRCHRNA7HTR3AHPGD | |
| SCHEMBL26200119 | 0.85 | EGFR (0.52) | EGFRKDREGLN2CHRNA7HTR3A | |
| SCHEMBL26206065 | 0.83 | KDR (0.44) | EGFRKDRALDH1A1KDM4EMAPT | |
| SCHEMBL13695368 | 0.81 | EGFR (0.49) | EGFRKDREGLN2CHRNA7HTR3A | |
| SCHEMBL26206088 | 0.81 | NPC1 (0.48) | EGFRKDRALDH1A1MAPTTSHR | |
| SCHEMBL26200121 | 0.79 | KDR (0.47) | EGFRKDRHPGDALDH1A1KDM4E | |
| SCHEMBL23746987 | 0.77 | KDR (0.45) | EGFRKDRCHRNA7HTR3AHPGD | |
| SCHEMBL26200122 | 0.76 | EGFR (0.44) | EGFRKDRHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | EGFR 3479/4885KDR 4681/4885EGLN2 771/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | EGFR 3479/4885KDR 4681/4885EGLN2 771/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | EGFR 3479/4885KDR 4681/4885EGLN2 771/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | EGFR 3479/4885KDR 4681/4885EGLN2 771/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | EGFR 3479/4885KDR 4681/4885EGLN2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.